PEG-MGF and growth hormone: how their action differs

PEG-MGF is marketed as a «long-acting» mechano-growth factor that supposedly competes with growth hormone. The editors examine what pegylation actually changes, why it works in registered GH drugs and why it does not rescue a molecule with an unproven effect.

PEG-MGF: what pegylation changes

PEG-MGF is a synthetic peptide of mechano-growth factor (the E-domain of the IGF-1Ec splice variant) with a polyethylene glycol (PEG) chain attached. MGF itself is a short peptide that is rapidly broken down by blood enzymes. Pegylation is intended as a way to prolong its existence in the body.

Pegylation technology is widely used in pharmacology. The flexible, water-soluble PEG chain increases the size of the molecule, so it is filtered by the kidneys more slowly, and partly «shields» it from proteases and the immune system. The review by Harris and Chess (2003) in Nature Reviews Drug Discovery describes how this approach changed the pharmacokinetics of many protein drugs.

However, pegylation is not only about prolonging action. PEG can reduce a molecule's affinity for its receptor, alter its distribution in tissues and its access to cells. For each pegylated drug these parameters are studied separately, and the result is not always predictable.

For PEG-MGF, no such human studies exist. It is not a registered medicine, and data on its pharmacokinetics, efficacy and safety in humans are absent. All that is known are the general principles of pegylation and contradictory preclinical data on MGF itself.

Growth hormone in the same light: long-acting forms and pegvisomant

Interestingly, pegylation is directly relevant to growth hormone too, but in registered, clinically studied drugs. Classic recombinant GH requires daily subcutaneous injections. In recent years long-acting forms have been registered that allow the drug to be given once a week; in one of them GH is bound to a PEG-based carrier and is gradually released unchanged.

Another example is pegvisomant. It is a modified and pegylated growth hormone molecule that blocks the GH receptor rather than activating it. Trainer and colleagues (2000) in the New England Journal of Medicine showed that pegvisomant normalizes IGF-1 in most patients with acromegaly. Here PEG not only prolongs action but also reduces antibody formation.

These examples are important for understanding: pegylation works when the target, mechanism and therapeutic window are known, and when every step is confirmed by clinical studies. For growth hormone all these elements exist. For PEG-MGF there is not even an agreed view of which receptor it should act on.

Thus, comparing PEG-MGF and GH means comparing a hypothetical molecule with an unknown target against a hormone whose pegylated forms have gone through the full drug development cycle.

Mechanisms of action: the known and the unknown

Growth hormone binds to the GH receptor, activates JAK2–STAT5 and stimulates the synthesis of IGF-1 in the liver and tissues. Direct effects include lipolysis and a counter-insulin action. These mechanisms are described in detail, in particular in the review by Møller and Jørgensen (2009).

For MGF, Goldspink's hypothesis predicted stimulation of muscle satellite cell proliferation. However, Fornaro and colleagues (2014) could not reproduce this effect under controlled conditions, and the review by Matheny and colleagues (2010) acknowledged that the receptor and mechanism of action of the E-peptide have not been established.

For the pegylated form, additional questions arise. Does the E-peptide with an attached PEG retain its activity? Does the large molecule penetrate from the blood into muscle tissue? Does it become a target of an immune response? For registered pegylated drugs these questions are answered by studies; for PEG-MGF there are no answers.

Thus, the claim that PEG-MGF «systemically does what MGF does locally» is marketing logic, not a scientific conclusion.

Risks: from hormone to polymer

The risks of excess growth hormone are fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, and with prolonged exposure — signs of acromegaly (Melmed, 2006). For long-acting GH forms there is the added issue of a persistently elevated hormone level between injections, which doctors monitor.

For PEG-MGF the risks have not been studied. One can only list the theoretical ones: unknown effect on the IGF-1 system, prolonged exposure in the event of an adverse reaction, the possibility of an immune response to PEG. It is known that some people have anti-PEG antibodies, which can speed the clearance of pegylated drugs and be associated with hypersensitivity reactions.

The practical risks of «research» peptides are the usual ones: mismatched content, poor pegylation quality, impurities, non-sterility. For pegylated products the quality of synthesis is especially important, because an insufficiently purified mixture may contain free PEG and unmodified peptide.

• Unknown target and unknown effect in humans.
• Prolonged action makes it harder to «roll back» an adverse reaction.
• A possible immune reaction to PEG.
• Absence of pharmaceutical quality control.

How to evaluate sellers' claims

Marketing descriptions of PEG-MGF often use scientific terms: «splice variant», «satellite cells», «pegylation extends the half-life». Each of these on its own corresponds to a real concept, but together they create an impression of proof that does not exist.

The editors advise asking a few questions. Are there randomized human studies of this specific molecule? Is its target known? Is there a marker by which to assess the effect? Is the product registered as a medicine? For PEG-MGF the answer to all of them is no.

By comparison: for growth hormone the answers to these questions are yes, but that does not make it a substance for self-administration. The systematic review by Liu and colleagues (2008) showed that even GH does not produce a proven improvement in athletic performance in healthy people.

For athletes there is an additional warning: mechano-growth factors are named directly in class S2 of the WADA prohibited list, regardless of any modification of the molecule.

Editorial conclusions

PEG-MGF is a pegylated version of the short mechano-growth factor peptide. Pegylation can prolong the molecule's action, but it cannot add an effect that has not been proven.

Growth hormone, by contrast, has a known receptor, mechanism and control marker, and its long-acting and pegylated derivatives have passed clinical studies and registration. Pegvisomant shows that PEG modification of GH can even turn an agonist into a receptor blocker.

PEG-MGF is not registered, human safety data are absent, and WADA prohibits it in class S2.

We also recommend reading our materials on MGF and IGF-1 splicing, on long-acting forms of growth hormone and on IGF-1 LR3.

References

1. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214–221.
2. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–1177.
3. Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151(3):865–875.
4. Fornaro M, Hinken AC, Needle S, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblast proliferation or differentiation. Am J Physiol Endocrinol Metab. 2014;306(2):E150–E156.
5. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–177.
6. Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148(10):747–758.
7. Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558–2573.
8. World Anti-Doping Agency. The World Anti-Doping Code: International Standard. Prohibited List. Montreal: WADA; 2024.